Role of interferons in demyelinating disease
Interferon beta lb (Betaseron®) was licensed by the U.S. Federal Food and Drug Administration in July 1993 as the first treatment to alter the natural history of multiple sclerosis (MS). The drug, injected subcutaneously every other day, reduced the frequency of relapses and the expansion of central white matter pathology as measured by MRI. Twelve previous interferon trials in MS, employing a variety of interferon preparations, doses and routes of administration, preceded this trial and provided the scientific foundation for its success. Beta interferon therapy probably inhibits gamma interferon to achieve its therapeutic effect. Future MS therapy may require combination treatment with multiple agents with complimentary immunologic effects.
KeywordsMultiple Sclerosis Multiple Sclerosis Patient Cerebral Spinal Fluid Interferon Beta Multiple Sclerosis Activity
Unable to display preview. Download preview PDF.
- Bornstein MB, Johnson KP (1992) Treatment of multiple sclerosis with copolymer I. In: Rudick RA, Goodkin DE (eds) Treatment of multiple sclerosis. Trial design, results and future perspectives. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
- IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661Google Scholar
- Johnson KP, Knobler RL, et al (1990) Recombinant human interferon beta treatment of relapsing-remitting multiple sclerosis: pilot study results. Neurology 40 [Suppl 1]: 261Google Scholar